Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 7—July 2021
Dispatch

Emergence of SARS-CoV-2 B.1.1.7 Lineage at Outpatient Testing Site, Berlin, Germany, January–March 2021

Welmoed van LoonComments to Author , Heike Rössig, Susen Burock, Jörg Hofmann, Julian Bernhard, Elisabeth Linzbach, Domenika Pettenkofer, Christian Schönfeld, Maximilian Gertler, Joachim Seybold, Tobias Kurth, and Frank P. Mockenhaupt
Author affiliations: Charité–Universitätsmedizin Berlin, Berlin, Germany (W. van Loon, H. Rössig, S. Burock, J. Bernhard, E. Linzbach, D. Pettenkofer, C. Schönfeld, M. Gertler, J. Seybold, T. Kurth, F.P. Mockenhaupt); Labor Berlin–Charité Vivantes GmbH, Berlin (J. Hofmann)

Main Article

Table

Characteristics of severe acute respiratory syndrome coronavirus 2–positive outpatients attending the Charité–Universitätsmedizin Berlin testing site, by lineages, Germany, January–March 2021*

Characteristic Wild-type lineage B.1.1.7 variant OR (95% CI)
Total no.
125
193
NA
Sex
M 69 (55.2) 94 (49.0)
F
56 (44.8)
98 (51.0)
1.3 (0.8–2.0)
Mean age, y (±SD)
36.6 (±13.8)
34.8 (±15.9)
1.8 (−1.5 to 5.1)†
Any symptoms 122 (97.6) 186 (96.4) 0.7 (0.2–2.6)
Self-reported fever in previous 48 h 48 (38.4) 82 (42.5) 1.2 (0.8–1.9)
Median self-reported temperature in case of fever, °C (±SD) 38.3 (±0.6) 38.2 (±0.7) 0.1 (−0.2 to 0.4)§
Shortness of breath 12 (9.6) 26 (13.5) 1.5 (0.7–3.0)
Fatigue 92 (73.6) 138 (71.5) 0.9 (0.5–1.5)
Chest pain 3 (2.4) 2 (1.0) 0.4 (0.1–2.6)
Diarrhea 19 (15.2) 24 (12.4) 0.8 (0.4–1.5)
Anosmia or ageusia (loss of smell or taste) 47 (37.6) 46 (23.8) 0.5 (0.3–0.9)
Muscle aches 75 (60.0) 116 (60.1) 1.0 (0.6–1.6)
Sore throat 52 (41.6) 104 (53.9) 1.6 (1.0–2.6)
Cough 61 (48.8) 98 (50.8) 1.1 (0.7–1.7)
Headache 86 (68.8) 133 (68.9) 1.0 (0.6–1.6)
Chills 44 (35.2) 67 (34.7) 1.0 (0.6–1.6)
Rhinorrhea
76 (60.8)
102 (52.8)
0.7 (0.5–1.1)
Median duration of symptoms upon test, d (25%–75% quantile)
3.0 (2.0–4.8)
3.0 (2.0–4.0)
0.0 (−1.0 to 0.0)§
Contact with person with confirmed SARS-CoV-2 infection 60 (48.0) 97 (50.3) 1.1 (0.7–1.7)
Median time between contact with person with confirmed 
SARS-CoV-2 infection and test, d (25%–75% quantile)
4.0 (1.2–7.0)
4.0 (1.0–6.0)
0.0 (−1.5 to 3.0)‡
Travel outside Berlin region in previous 14 d
12 (9.6)
36 (18.7)
2.2 (1.1–4.3)
Median Ct value (25%–75% quantile) 20.2 (17.4–24.1) 20.1 (17.1–22.8) 0.1 (−0.9 to 1.6)‡
Symptom duration <7 d, no. patients (median Ct value 
[25%–75% quantile]) 113 (19.9 [17.4–23.5]) 171 (19.5 [16.6–22.6]) 0.4 (−1.0 to 1.7)‡
Symptom duration >7 d, no. patients (median Ct value 
[25%–75% quantile]) 6 (30.1 [26.1–31.3]) 11 (26.2 [21.4–31.2]) 3.9 (−5.6 to 10.0)‡

*Values are no. (%) except as indicated. Ct, cycle threshold; NA, not applicable; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†Difference in means (95% CI).
‡Difference in medians (95% CI). The 95% CI for difference in medians was computed by a percentile bootstrap with 1,000 replications.

Main Article

Page created: May 10, 2021
Page updated: June 17, 2021
Page reviewed: June 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external